EQT life science
EQT Life Science develops medications, devices, and methods to combat it.
Business Model:
Revenue: $42.9M
Employees: 11-50
Rankings
Industries / Tags:
Detailed EQT life science Information
EQT life science was acquired by
EQT.
The acquisition happend on 2021-11-10.
Details of the transaction were not public
Acquirer
Geographic Data
Address: Johannes Vermeerplein 9
City: Amsterdam
State: noord-holland
Zip: 1071 DV
Country: NL
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Linkedin
Crunchbase
Metrics
4,837,703Website Global Rank
2,148Website Monthly Traffic
Twitter Followers
Description
EQT life science develops innovative medicines, devices and tools to address the single most important thing that matters to all the preservation of health. The organization believes that such opportunities add value to all stakeholders.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2014 | Affimed | Series E | 0 |
| 1/2016 | ViCentra | Series B | 10.9M |
| 5/2020 | Arvelle Therapeutics | Series A | 0 |
| 9/2016 | Immunic Therapeutics | Series A | 19.6M |
| 8/2007 | FlowCardia | Series C | 0 |
| 8/2007 | Isto Technologies | Series E | 0 |
| 2/2010 | Promethera Biosciences | Series A | 7.3M |
| 11/2011 | Harvest Automation | Series B | 7.9M |
| 11/2003 | Affectis Pharmaceuticals | Series A | - |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 4/2000 | NewBiotics | Venture Round | 6.3M |
| 9/2021 | Amolyt Pharma | Series B | 0 |
| 5/2011 | Cobalt Technologies | Series D | 0 |
| 1/2009 | BMEYE | Series A | - |
| 10/2015 | Luxendo | Series A | 0 |
| 9/2019 | Pharvaris | Series B | 66M |
| 1/2011 | Nexstim | Venture Round | 0 |
| 8/2018 | Artios Pharma | Series B | 0 |
| 6/2009 | Pronota | Series B | 7.4M |
| 5/2019 | DNA Script | Series B | 38.5M |
| 6/2022 | ImCheck Therapeutics | Series C | 0 |
| 7/2020 | Cybin | Series B | 0 |
| 3/2014 | Hybrigenics | Post-IPO Equity | 8.4M |
| 12/2007 | Vivendy Therapeutics | Series A | 15.4M |
| 5/2016 | Nouscom | Series A | 13.6M |
| 11/2017 | Xeltis | Series C | 53M |
| 4/2004 | NewBiotics | Series E | 4.6M |
| 5/2008 | Asoyia | Venture Round | 4M |
| 2/2022 | Perfuze | Series A | 0 |
| 7/2021 | Artios Pharma | Series C | 0 |
| 2/2009 | ActoGeniX | Private Equity Round | 17.4M |
| 4/2014 | Heart Metabolics | Series A | 20M |
| 1/2007 | 4-Antibody AG | Series A | 18.4M |
| 10/2012 | Cobalt Technologies | Venture Round | 5M |
| 3/2019 | SNIPR Biome | Series A | 50M |
| 12/2014 | Xeltis | Series B | 33.5M |
| 4/2005 | DNage | Series A | 1.9M |
| 1/2016 | Pharvaris | Series A | 16.3M |
| 4/2006 | Pronota | Series A | 7.8M |
| 1/2010 | Merus | Series B | 0 |
| 4/2012 | Cobalt Technologies | Venture Round | 2.9M |
| 1/2005 | OctoPlus | Series B | 23.9M |
| 5/2018 | Rainier Therapeutics | Series B | 20M |
| 2/2007 | Prosensa | Series A | 18M |
| 9/2010 | Harvest Automation | Series A | 1.3M |
| 10/2013 | Harvest Automation | Series C | 11.8M |
| 5/2003 | Santarus | Series D | 51.4M |
| 7/2017 | Simplify Medical | Series B | 21M |
| 2/2018 | Simplify Medical | Series B | 23M |
| 3/2007 | Okairos | Series A | 9.6M |
| 11/2009 | Kreatech Diagnostics | Venture Round | 0 |
| 10/2007 | Hyperion Therapeutics | Debt Financing | 15M |
| 9/2007 | Nexstim | Venture Round | 10.9M |
| 4/2016 | Onward | Series A | 29.5M |
| 10/1999 | Devgen | Series B | 24.7M |
| 1/2012 | Pronota | Series C | 4.8M |
| 1/2007 | Movetis | Series A | 63.8M |
| 2/2010 | arGEN-X | Series A | 4.5M |
| 12/2021 | ViCentra | Series C | 0 |
| 3/2010 | Seahorse Bioscience | Series D | 5M |
| 10/2015 | Sequana Medical | Series C | 0 |
| 8/2021 | Visus Therapeutics | Equity | 20M |
| 6/2020 | OneProjects | Series A | 12.4M |
| 1/2010 | Harvest Automation | Series A | 4M |
| 2/2007 | ActoGeniX | Venture Round | 26.1M |
| 7/2019 | AM Pharma | Series F | 130.1M |
| 1/2019 | INNOVO by Atlantic Therapeutics | Series B | 32.1M |
| 11/2012 | Kiadis Pharma | Venture Round | 0 |
| 7/2001 | NewBiotics | Series C | 0 |
| 9/2016 | Vivasure Medical | Series C | 18.3M |
| 9/2017 | Immunic Therapeutics | Series A | 11.9M |
| 2/2006 | EyeSense AG | Series A | 0 |
| 2/2023 | Xeltis | Series D | 0 |
| 8/2022 | eTheRNA immunotherapies | Series B | 0 |
| 6/2022 | Ariceum Therapeutics | Series A | 0 |
| 7/2002 | Scion Pharmaceuticals | Series B | 0 |
| 12/2006 | BMEYE | Series A | - |
| 7/2020 | DNA Script | Series B | 50M |
| 7/2003 | PamGene | Series B | 11.3M |
| 8/2015 | Kuros Biosciences | Post-IPO Equity | 15.3M |
| 8/2006 | Pronota | Series A | 10.6M |
| 5/2021 | Binx Health | Series E | 0 |
| 7/2019 | Amolyt Pharma | Series A | 0 |
| 11/2014 | Curetis | Series B | 0 |
| 10/2021 | DNA Script | Series C | 0 |
| 6/2011 | Sapiens Steering Brain Stimulation | Series A | 18.7M |
| 11/2009 | Vivoryon Therapeutics | Series B | 0 |
| 1/2012 | Vivoryon Therapeutics | Venture Round | 19.4M |
| 8/2007 | BioProcessors | Series C | 10M |
| 12/2018 | XyloCor Therapeutics | Series A | 17M |
| 4/2007 | Affimed | Series B | 32M |
| 8/2016 | Rotation Medical | Series B | 12M |
| 10/2012 | Affimed | Series D | 20.1M |
| 7/2014 | Rotation Medical | Series B | 27.2M |
| 1/2021 | Neurent Medical | Series B | 0 |
| 12/2009 | Curetis | Series A | 27.9M |
| 7/2009 | Pasteuria Bioscience | Series B | 0 |
| 2/2019 | Arvelle Therapeutics | Series A | 0 |
| 12/2000 | PamGene | Series A | 6.2M |
| 7/2021 | Xilis | Series A | 0 |
| 6/2015 | Neuravi | Series B | 21.5M |
| 3/2021 | XyloCor Therapeutics | Series A | 0 |
| 5/2023 | VarmX | Series B | 0 |
| 1/2012 | Prosensa | Venture Round | 0 |
| 6/2007 | Kiadis Pharma | Venture Round | 0 |
| 10/2007 | Syntaxin | Series B | 32M |
| 10/2021 | OneProjects | Series A | 8M |
| 2/2018 | Merus | Post-IPO Equity | 55.8M |
| 12/2021 | AviadoBio | Series A | 0 |
| 7/2020 | ViCentra | Venture Round | 0 |
| 7/2011 | Binx Health | Series B | 27.1M |
| 9/2012 | IlluminOss Medical | Series C | 0 |
| 11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
| 9/2019 | Nkarta Therapeutics | Series B | 114M |
| 1/2017 | Binx Health | Series D | 0 |
| 3/2023 | QurAlis | Series B | 0 |
| 12/2015 | Xeltis | Series B | 3.3M |
| 10/2013 | Merus | Series B | 42.2M |
| 3/2015 | Cardiac Dimensions | Equity | 15.2M |
| 10/2008 | Cobalt Technologies | Series C | 0 |
| 9/2018 | Endotronix | Series D | 0 |
| 4/2015 | Merus | Series C | 79.1M |
| 9/2020 | Cardiac Dimensions | Series C | 17.5M |
| 3/2016 | eTheRNA immunotherapies | Series A | 26.6M |
| 8/2021 | T-knife | Series B | 110M |
| 8/2016 | Mint Solutions | Series B | 5.6M |
| 5/2017 | ImCheck Therapeutics | Series A | 21.9M |
| 5/2017 | Cardior Pharmaceuticals | Series A | 16.3M |
| 3/2004 | 4-Antibody AG | Seed Round | 2.1M |
| 7/2014 | Mint Solutions | Series A | 6M |
| 10/2021 | Egle Therapeutics | Series A | 0 |
| 5/2012 | Celladon | Venture Round | 10M |
| 5/2003 | BioXell | Series B | 19.9M |
| 7/2020 | Vico Therapeutics | Series A | 31M |
| 4/2014 | Binx Health | Series B | 0 |
| 4/2020 | FoRx Therapeutics | Seed Round | 10.8M |
| 11/2009 | Cellerix | Series B | 40.5M |
| 9/2007 | Cellerix | Series B | 37.2M |
| 11/2017 | Orphazyme | Post-IPO Equity | 0 |
| 4/2021 | Onward | Venture Round | 0 |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 3/2017 | Rainier Therapeutics | Series B | 30M |
| 7/2020 | VarmX | Series B | 36.3M |
| 11/2016 | OxThera | Series D | 34.1M |
| 1/2010 | Cellerix | Series C | 37.7M |
| 8/2021 | Cardior Pharmaceuticals | Series B | 0 |
| 4/2023 | Evommune | Series B | 50M |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 4/2020 | Kiadis Pharma | Post-IPO Equity | 5.5M |
| 1/2010 | Kreatech Diagnostics | Series B | 0 |
| 1/2016 | Rainier Therapeutics | Series A | 13M |
| 6/2011 | Mendor | Series B | 11.7M |
| 4/2023 | Evommune | Series B | 0 |
| 3/2023 | QurAlis | Series B | 0 |
| 2/2023 | Xeltis | Series D | 0 |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 8/2022 | eTheRNA immunotherapies | Series B | 0 |
| 6/2022 | ImCheck Therapeutics | Series C | 0 |
| 6/2022 | Ariceum Therapeutics | Series A | 0 |
| 2/2022 | Perfuze | Series A | 0 |
| 12/2021 | ViCentra | Series C | 0 |
| 12/2021 | AviadoBio | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
